Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) announced that the independent Compensation Committee of its Board approved equity inducement awards for one non-executive employee under the 2025 Employment Inducement Incentive Award Plan. The grant consists of options to purchase an aggregate of 19,425 ordinary shares, approved on July 31, 2026, and intended to be material to the employee’s acceptance of employment in line with Nasdaq Listing Rule 5635(c)(4).

The stock options have a 10-year term and an exercise price of $14.47, equal to Crescent’s July 31, 2026 Nasdaq closing price. Vesting occurs as to one-fourth of the shares on the first anniversary of the employee’s start date, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and the applicable option agreement.

Market Context

Net Buying insider sentiment provides context for this employee-award notice, while two prior compar...

Analysis

Net Buying insider sentiment provides context for this employee-award notice, while two prior comparable announcements recorded negative 24-hour reactions of -4.29% and -3.02%. The active S-3 shelf remains a disclosed capital-markets risk.

Key Figures

Inducement award shares: 19,425 shares Approval date: July 31, 2026 Option term: 10 years +3 more

6 metrics

Inducement award shares 19,425 shares One non-executive employee

Approval date July 31, 2026 Options approved by the Compensation Committee

Option term 10 years Granted options

Exercise price $14.47 Equal to the July 31, 2026 closing price

Initial vesting One-fourth (1/4th) of shares On the first anniversary of the employee’s start date

Subsequent vesting One-forty-eighth (1/48th) of shares Monthly thereafter, subject to continuous service

Historical Context

5 past events · Latest: Jul 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 23	Inducement award grant	Neutral	-4.3%	Options covering 52,500 shares were granted to two non-executive employees.
Jul 16	Public offering closing	Negative	-2.4%	Offering closed with 9,387,896 shares and 525,897 pre-funded warrants issued.
Jul 14	Public offering pricing	Negative	+2.4%	Offering priced shares at $14.50 and pre-funded warrants at $14.499.
Jul 14	Proposed public offering	Negative	+2.4%	Proposed offering included a 30-day option for additional shares.
Jun 26	Inducement award grant	Neutral	-3.0%	Options covering 65,100 shares were granted to three non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two prior inducement-award announcements were followed by negative 24-hour reactions, while offering-related reactions were mixed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 19,425 shares of the Company’s ordinary shares to one non-executive employee as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on July 31, 2026 and were material to the employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $14.47, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on July 31, 2026. The options granted to the employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contacts

Investors

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com 
617-465-0586

Media

Jenna Poist 
Director, Corporate Communications 
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

What inducement stock option awards did Crescent Biopharma (CBIO) grant on July 31, 2026?

Crescent Biopharma granted options to purchase 19,425 ordinary shares to one non-executive employee. According to Crescent Biopharma, these inducement awards were approved on July 31, 2026 under the 2025 Employment Inducement Incentive Award Plan and were material to the employee’s acceptance.

What is the exercise price and term of the new Crescent Biopharma (CBIO) inducement options?

The inducement stock options have an exercise price of $14.47 and a 10-year term. According to Crescent Biopharma, the price equals the closing price of its ordinary shares on Nasdaq on July 31, 2026, when the options were approved.

How do the Crescent Biopharma (CBIO) inducement awards vest for the new employee?

The options vest 25% on the first anniversary of the employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vests each month after year one, subject to the employee’s continuous service with the company.

Under which plan were the Crescent Biopharma (CBIO) inducement stock options granted?

The options were granted under the 2025 Employment Inducement Incentive Award Plan, as amended. According to Crescent Biopharma, the awards are also governed by an individual option agreement that sets out the specific terms and conditions of the applicable grant.

How do Crescent Biopharma (CBIO) inducement awards comply with Nasdaq Listing Rule 5635(c)(4)?

The options were granted as a material component of the employee’s decision to join Crescent Biopharma. According to Crescent Biopharma, this structure is intended to satisfy Nasdaq Listing Rule 5635(c)(4), which permits equity grants as inducements for new employees.

Who received the August 2026 Crescent Biopharma (CBIO) inducement option grant and why?

One non-executive employee received options to buy 19,425 shares as an inducement to employment. According to Crescent Biopharma, the grant was considered material to the employee’s acceptance of the position and was approved by the Board’s Compensation Committee.